OrthogenRx, Inc. is a medical device company focused on the development and commercialization of treatments for musculoskeletal conditions including osteoarthritis (OA). Our first commercial product is GenVisc® 850 (sodium hyaluronate)* indicated for the treatment of osteoarthritic knee pain.
*GenVisc 850 prescribing informationOrthogenRx senior management has over 50 years’ experience in the biopharma industry and 30 years’ experience with the sales, marketing and reimbursement of products in the targeted class of medical devices. Board members and leading advisors include expertise in FDA law and regulations, reimbursement, emerging company management and investment, sales & marketing and mergers & acquisitions, as well as includes nationally recognized law firms in intellectual property law and general corporate counsel, all contributing to a world class management and advisory team.
Michael Daley
CEO/Founder
25+ year career in biopharmaceutical/device industries. Former Medical Director for Hyalgan (first Hyaluronic Acid Approved in US) and is widely known for his expertise in the HA market.
Frank Gallagi
Chief Financial Officer
Over 20 years experience in the private equity/venture industry, holding senior management positions at New Age Ventures, Metropolitan Equity and FGII Ventures.
David Toledo
Sr. Vice President - Manufacturing, Quality and Alliances
20+ years experience in pharmaceuticals with specific focus on product development and drug delivery.
Lynne Budnovitch
Vice President - Operations
Numerous senior management positions including Managing Director in Enterprise Resourcing, IT Security and education/training systems.
Ken Long
Vice President – Market Access & Key Accounts
Over 30 years of healthcare experience most recently in commercial leadership roles at Bioventus/Smith & Nephew. Specific areas of expertise in reimbursement and market access.